Published July 2016 | Version v1
Journal article Metadata-only

Phase I trial of 18F-Fludeoxyglucose based radiation dose painting with concomitant cisplatin in head and neck cancer

Creators

  • 1. Rigshospitalet, Department of Oncology, Section of Radiotherapy, University of Copenhagen (Denmark)
  • 2. Rigshospitalet, Department of Clinical Physiology, Nuclear Medicine and PET, University of Copenhagen (Denmark)
  • 3. Division of Biostatistics and Bioinformatics, University of Maryland Greenebaum Cancer Center and Department of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore (United States)

Description

Purpose: The CONTRAST (CONventional vs.Tumor Recurrence Adapted Specification of Target dose) phase I trial tested the safety of FDG PET guided dose redistribution in patients receiving accelerated chemo-radiotherapy for locally advanced head and neck squamous cell carcinoma (HNSCC).

Availability note (English)

Available from http://dx.doi.org/10.1016/j.radonc.2016.03.005

Additional details

Identifiers

DOI
10.1016/j.radonc.2016.03.005;
PII
S0167814016001274;

Publishing Information

Journal Title
Radiotherapy and Oncology
Journal Volume
120
Journal Issue
1
Journal Page Range
p. 76-80
ISSN
0167-8140
CODEN
RAONDT

INIS

Country of Publication
Ireland
Country of Input or Organization
International Atomic Energy Agency (IAEA)
INIS RN
50080945
Subject category
S62: RADIOLOGY AND NUCLEAR MEDICINE;
Descriptors DEI
CARCINOMAS; FLUORINE 18; HEAD; NECK; PATIENTS; POSITRON COMPUTED TOMOGRAPHY; RADIATION DOSES; RADIOTHERAPY
Descriptors DEC
BETA DECAY RADIOISOTOPES; BETA-PLUS DECAY RADIOISOTOPES; BODY; COMPUTERIZED TOMOGRAPHY; DIAGNOSTIC TECHNIQUES; DISEASES; DOSES; EMISSION COMPUTED TOMOGRAPHY; FLUORINE ISOTOPES; HOURS LIVING RADIOISOTOPES; ISOMERIC TRANSITION ISOTOPES; ISOTOPES; LIGHT NUCLEI; MEDICINE; NANOSECONDS LIVING RADIOISOTOPES; NEOPLASMS; NUCLEAR MEDICINE; NUCLEI; ODD-ODD NUCLEI; RADIOISOTOPES; RADIOLOGY; THERAPY; TOMOGRAPHY

Optional Information

Copyright
Copyright (c) 2017 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.